Actively Recruiting
Evaluating the Safety and Effects of AGN-151607-DP in Adults With Upper Limb Essential Tremor Using Randomized, Placebo-Controlled Injections
Led by AbbVie · Updated on 2026-10-27
94
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Upper limb essential tremor UL ET is a movement disorder that causes shaking in the hands and forearms, making everyday tasks like writing, pouring, and eating difficult. This research evaluates the safety and effects of AGN-151607-DP, an investigational drug, in adults with UL ET. Approximately 94 participants will be enrolled across about 40 sites in the United States and Canada to assess adverse events and changes in disease activity. Participants will be randomly assigned to receive intramuscular injections of either AGN-151607-DP or a matching placebo. The study uses a parallel design with a triple-blind approach to compare the investigational drug against placebo. The treatment period and follow-up last approximately 72 weeks, including an open-label period to further evaluate the drugs effects and safety. During the study, participants will complete questionnaires and undergo medical assessments to monitor side effects and disease activity. The main outcomes measured are changes from baseline in the Essential Tremor Rating Assessment Scale TETRAS and the number of participants experiencing adverse events over 72 weeks. Secondary measures include upper limb tremor severity and clinical global impression of severity. The study aims to understand the treatments impact and monitor participant safety throughout the long-term follow-up.
CONDITIONS
Brief Title
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here